Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 9, 2011, Pages 2141-2149

  de Boer, Ian H ^a   Katz, Ronit ^a   Chonchol, Michel ^b   Ix, Joachim H ^c   Sarnak, Mark J ^d   Shlipak, Michael G ^e   Siscovick, David S ^a   Kestenbaum, Bryan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANTIHYPERTENSIVE AGENT; PARATHYROID HORMONE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; DEATH; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; VITAMIN BLOOD LEVEL;

AGED; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; PROSPECTIVE STUDIES; VITAMIN D;

EID: 80052606610     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02640311     Document Type: Article

References (50)

1. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266. 2002
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
3. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352: 2049-2060, 2005
4. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145: 237-246, 2006
5. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ: Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 168: 2212-2218, 2008
6. de Boer IH, Katz R, Cao JJ, Fried LF, Kestenbaum B, Mukamal K, Rifkin DE, Sarnak MJ, Shlipak MG, Siscovick DS: Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care 32: 1833-1838, 2009
7. Al-Aly Z, Zeringue A, Fu J, Rauchman MI, McDonald JR, El-Achkar TM, Balasubramanian S, Nurutdinova D, Xian H, Stroupe K, Abbott KC, Eisen S: Rate of kidney function decline associates with mortality. J Am Soc Nephrol 21: 1961-1969, 2010
8. Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 41: 11-17, 2003
9. Li YC: Renoprotective effects of vitamin D analogs. Kidney Int 78: 134-139, 2010
10. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002
11. Durvasula RV, Shankland SJ: The renin-angiotensin system in glomerular podocytes: Mediator of glomerulosclerosis and link to hypertensive nephropathy. Curr Hypertens Rep 8: 132-138, 2006
12. Giovannini L, Panichi V, Migliori M, De Pietro S, Bertelli AA, Fulgenzi A, Filippi C, Sarnico I, Taccola D, Palla R, Bertelli A: 1,25-Dihydroxyvitamin D(3) dose-dependently inhibits LPS-induced cytokines production in PBMC modulating intracellular calcium. Transplant Proc 33: 2366-2368, 2001
13. Reichel H, Koeffler HP, Tobler A, Norman AW: 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 84: 3385-3389, 1987
14. Panichi V, De Pietro S, Andreini B, Bianchi AM, Migliori M, Taccola D, Giovannini L, Tetta C, Palla R: Calcitriol modulates in vivo and in vitro cytokine production: A role for intracellular calcium. Kidney Int 54: 1463-1469, 1998
15. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K: 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286: F526-F533, 2004
16. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105: 15896-15901, 2008
17. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998
18. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158: 1733-1741, 2001
19. Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T, Fukushima N, Doi T: 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 17: 2132-2137, 2002
20. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC: Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 77: 1000-1009, 2010
21. de Boer IH, Kestenbaum B: Vitamin D in chronic kidney disease: Is the jury in? Kidney Int 74: 985-987, 2008
22. Institute of Medicine of the National Academies, Committee to Review Dietary Reference Intakes for Vitamin D and Calcium: Dietary Reference Intakes for Calcium and Vitamin D, Washington, D.C., The National Academies Press, 2011
23. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
24. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al.: The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1: 263-276, 1991
25. Agborsangaya C, Toriola AT, Grankvist K, Surcel HM, Holl K, Parkkila S, Tuohimaa P, Lukanova A, Lehtinen M: The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione. Nutr Cancer 62: 51-57
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
27. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP: Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41: 264-270, 1995
28. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33: 278-285, 1985
29. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD, 3rd, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51: 395-406, 2008
30. Robinson-Cohen C, Katz R, Mozaffarian D, Dalrymple LS, de Boer I, Sarnak M, Shlipak M, Siscovick D, Kestenbaum B: Physical activity and rapid decline in kidney function among older adults. Arch Intern Med 169: 2116-2123, 2009
31. Standards of medical care in diabetes-2007. Diabetes Care 30[Suppl 1]: S4-S41, 2007
32. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Bethesda, MD, National Institutes of Health, 2004
33. Wang Y, Jacobs EJ, McCullough ML, Rodriguez C, Thun MJ, Calle EE, Flanders WD: Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: Insights from simulations based on serum 25-hydroxyvitamin D. Am J Epidemiol 170: 88-94, 2009
34. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ: Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77: 204-210, 2003
35. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008
36. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med 168: 1174-1180, 2008
37. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS: 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 20: 1805-1812, 2009
38. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ: Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7: 439-443, 1997
39. Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: A0828, 2000
40. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS: 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 50: 69-77, 2007
41. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, Raymond NT, Howie AJ, Cockwell P, Stewart PM, Hewison M: Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 74: 1343-1353, 2008
42. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005
43. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 52: 249-255, 2008
44. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376: 1543-1551, 2010
45. Chonchol M, Scragg R: 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 71: 134-139, 2007
46. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75: 88-95, 2009
47. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P: 25-Hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 20: 2631-2639, 2009
48. Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Fowlkes JL: Enhanced excretion of vitamin D binding protein in type 1 diabetes: A role in vitamin D deficiency? J Clin Endocrinol Metab 96: 142-149, 2011
49. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 429- 435, 2004
50. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 18: 2600-2608, 2007